Pharmaceutical Technology

DECEMBER 5, 2022

Incyte has signed a partnership and licence agreement with CMS subsidiary CMS Aesthetics to develop and market ruxolitinib cream to treat autoimmune and inflammatory dermatologic ailments in Greater China and some Southeast Asian countries. Incyte will also receive royalty payments on the net product sales in the territory of CMS.

FDA 52

FDA 52

Viseven

MAY 15, 2023

Pharmaceutical detailing is the most time-tested marketing format in the medical content world. Old-timer sales reps should remember how pharmaceutical companies reckoned face-to-face (F2F) visits with doctors as the most effective approach to achieving their sales targets. What is Pharmaceutical Detailing?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Patient Care 52

Pharmaceutical Technology

AUGUST 28, 2022

In the 92 low- and middle-income countries in the GAVI COVAX Advance Market Commitment (AMC 92), the company said it will not impose its patents on any Covid-19 vaccines. It has no plans to seek removal of Comirnaty from the market and will not seek an injunction to stop its sale in the future.

Vaccines 98

Vaccines 98

Pharmaceutical Technology

DECEMBER 8, 2022

According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K.

Communication 122

Communication Immunization Hospitals 122

Pharma Marketing Network

NOVEMBER 6, 2020

The Pharma Marketing Wire is the bi-monthly e-newsletter of the Pharma Marketing Network® (PMN), which features original articles from pharmaceutical marketing experts and industry executives. Please email us a topic/topics you wish to submit an article about to publisher@pharma-mkting.com. Physician marketing.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies 40

Digital Pharmacist

JANUARY 16, 2023

Creating a 2023 health awareness calendar this year is a great way to market your pharmacy while promoting patient health. . They’re also a great addition to your pharmacy’s marketing strategy, allowing you to develop relationships with your audience while advertising relevant products and services. Not feeling well-rested?

Immunization 98

Immunization Vaccines Communication Hospitals 98

Pharmaceutical Technology

MAY 10, 2023

While the government said that Gilead secured its PrEP approvals only after CDC’s research on the topic, the company stated that there already were published materials on the potential use of antiretroviral therapies as PrEP prior to this. Gilead markets both Truvada and its successor Descovy.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies FDA 105

pharmaphorum

APRIL 30, 2021

It’s fair to say this is the most interesting time ever for market access. We take a look at all these intersecting topics in this issue – with experts from across the industry sharing their advice on how companies can navigate these paradigm shifts. Time for a NICE change. How will NICE fare in a post-Brexit world?

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Communication Vaccines 98

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. Topic sponsors are not involved in the creation of editorial content. The companies entered the initial agreement in September last year. Free Whitepaper.

Communication 131

Communication 131

Pharmaceutical Technology

AUGUST 4, 2022

According to the deal, Poseida will offer either exclusive rights or options to Roche for developing and marketing various allogeneic CAR-T programmes in its portfolio targeting hematologic malignancies. Furthermore, Roche will oversee the late-stage clinical development and worldwide marketing of all products under the alliance.

59

59

pharmaphorum

FEBRUARY 28, 2022

Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing application for Oleogel-S10, its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Read Faith’s story and more personal stories at [link] & share them on your social media to help raise awareness!

FDA 98

FDA 98

Viseven

JUNE 12, 2023

The global pharmaceutical market is becoming more digitalized, insight-driven, and consumer-centric. In this article, we’ll focus on a pharmaceutical market in the APAC region, go through the differences between pharma in APAC and pharma in other parts of the world, and see the current state of the APAC pharma market.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Packaging 52

Viseven

JULY 26, 2023

Collision is one of the world’s biggest tech conferences where businesses, leaders, investors, designers, developers, marketers, media, innovation enthusiasts, and artificial intelligence (AI) evangelists engage with each other, share knowledge, and learn how technology is transforming global business. The event’s schedule was massive.

Communication 52

Communication 52

pharmaphorum

OCTOBER 28, 2022

In 2018, she was nominated by Pharmaceutical Marketing Europe as one of the 30 most influential women in UK Healthcare, and in September 2019 appointed by the UK’s Chief Scientific Officer to be an Ambassador for Women in Science and Engineering (WISE). She is an SME in market access, rare disease and biosimilars.

121

121

Viseven

OCTOBER 3, 2023

Viseven and Veeva have been partners for many years, providing advanced technology and content expertise to pharma and life sciences businesses and agencies of all sizes, and it was a big honor and privilege for the Viseven team to be at the event and make its own contribution to the evolution of biopharma digital marketing.

52

52

Pharmaceutical Technology

DECEMBER 14, 2022

Additionally, for WVE-006, GSK will make development and launch milestone payments of up to $225m to Wave, which is also eligible to get up to $300m in milestone payments based on sales. On completion of the first-in-patient clinical trial by Wave, GSK will be in charge of the development and marketing works. Free Whitepaper.

Communication 64

Communication FDA 64

Pharmaceutical Technology

DECEMBER 12, 2022

The development, clinical trial and marketing expenses for the cell therapy will be shared by the companies while co-commercialising the product and equally splitting profits from the US region. Kite will oversee the marketing of the product outside the US while Arcellx is eligible for royalty payments on sales. Free Whitepaper.

Communication 105

Communication 105

pharmaphorum

MAY 31, 2022

At the moment, treatment typically involves oral or topical corticosteroids, antihistamines and some antidepressant drugs, but responses are often inadequate, vary widely between patients, and come with the burden of safety risks if used long-term. billion) a year and some analysts predicting levels could go as high as $12.5

FDA 115

FDA 115

Pharma Marketing Network

OCTOBER 5, 2020

In response to this week’s DHC Virtual Summit with Novartis, Mark Bard, Co-founder/Managing Partner, DHC, talked one-on-one with Justin Grossman about how the COVID pandemic will change the world of digital healthcare marketing. Tech infrastructure and time to market needs to improve. Here are some highlights from their discussion.

Communication 98

Communication 98

Pharma Marketing Network

OCTOBER 5, 2020

In response to this week’s DHC Virtual Summit with Novartis, Mark Bard, Co-founder/Managing Partner, DHC, talked one-on-one with Justin Grossman about how the COVID pandemic will change the world of digital healthcare marketing. Tech infrastructure and time to market needs to improve. Here are some highlights from their discussion.

Communication 98

Communication 98

pharmaphorum

MAY 25, 2022

Vtama (tapinarof) – originally developed by GlaxoSmithKline – is a first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) and has been approved by the US regulator with a broad label spanning mild, moderate, and severe psoriasis and an unlimited duration of use. Otezla – which Amgen acquired for $13.4

FDA 52

FDA Labelling 52

Pharmaceutical Technology

MAY 16, 2023

This comes with an upfront cash payment of $375 million, with a potential additional $25 million if Hemgenix net sales reach a certain milestone in 2024, based on a May 15 announcement. Additionally, UniQure was set to get tiered royalties of up to “a low-twenties percentage” of net product sales related to Hemgenix.

FDA 52

FDA 52

PharmaShots

JANUARY 23, 2023

Until recently, there were very few topical options available for treating plaque psoriasis long-term. Typically, some patients start with topical steroids; however, these can be challenging, as many are limited by where they can be applied on the body and for how long and how often they can be used. [i] of VTAMA cream?

FDA 40

FDA Labelling Immunization 40

Pharma Marketing Network

JULY 21, 2023

Some examples of content you could share include: news articles about new drugs or treatments, blog posts about your work in the pharmaceutical industry, or white papers on industry-related topics. Sales Navigator offers a variety of features that can help you target your outreach and track your results.

52

52

Druggist

DECEMBER 9, 2020

Sale of some anti-itch creams is restricted to pharmacies only. Lastly, I touch on the management of skin itchiness with a combination treatment of a topical product(s) and oral antihistamines. Skin itch caused by skin dryness is initially managed with topical emollients applied to the skin. Skin itchiness caused by drugs.

Compounding 97

Compounding People Management 97

pharmaphorum

MAY 17, 2021

Many life sciences companies have begun 2021 by reviewing how they respond to the longer-term impact of this change, and its impact on field teams is a major topic. Many life sciences companies have begun 2021 by reviewing how they respond to the longer-term impact of this change – and its impact on sales forces is a major topic.

Communication 72

Communication 72

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. Topic sponsors are not involved in the creation of editorial content.

Vaccines 59

Vaccines Research Laboratories Packaging 59

pharmaphorum

SEPTEMBER 22, 2021

The FDA has approved Incyte’s Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Analysts said that the warning, which follows an FDA review of the safety of the JAK inhibitor class, could put a brake on sales of the new drug.

FDA 52

FDA Labelling 52

PharmaShots

JUNE 14, 2023

We were fortunate to have Preethi Warrier (Application Engineer - Solution Support) at Agilent Technologies and Aparna Gupta (Account Manager - Service and Sales Division) as our keynote speakers alongside with Ankush Sharma (Regional Marketing Program Manager – Service & Enterprise Channel) at Agilent Technologies.

49

49

pharmaphorum

DECEMBER 21, 2020

It marks something of a departure from AZ’s relentless focus on deal-making in oncology , its top product category, and also comes as Alexion has been locked in a battle with activist shareholders pushing for a sale. Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017.

Chemotherapy 126

Chemotherapy Immunization FDA 126

Pharmaceutical Technology

AUGUST 24, 2022

Prevail will also handle the complete production, clinical development and marketing activities. In the future, Prevail will also make tiered royalty payments based on net sales of the products that use capsids covered under the partnership. . Topic sponsors are not involved in the creation of editorial content.

52

52

DiversifyRx

AUGUST 19, 2022

Lisa Faast – Video Marketing For Increased Pharmacy Profits. Video marketing is vital for social media algorithms and getting the word about your pharmacy. Video marketing is free marketing, and people love it. You can learn more about video marketing here. Allan Dib – One Page Marketing Plan.

Independent Pharmacies 98

Independent Pharmacies Patient Care 98

Pharmaceutical Technology

FEBRUARY 17, 2023

Additionally, Capricor will receive up to $89m in further development and sales-based milestones, along with a double-digit share of revenue based on product sales. Topic sponsors are not involved in the creation of editorial content. According to the deal, Capricor will receive $12m in upfront payment from Nippon Shinyaku.

Labelling 52

Labelling Communication 52

DiversifyRx

AUGUST 18, 2023

Sexual Health: Men’s sexual health has been a popular topic in independent pharmacies for some time now, and for good reason, but when it comes to women’s sexual health, we often do not look past hormones. Speaking of winners… don’t discount the fun marketing that can be done with these products too!

Independent Pharmacies 52

Independent Pharmacies Packaging Patient Care Immunization 52

pharmaphorum

DECEMBER 22, 2021

Crucially, it extends the label for the PDE 4 inhibitor to include people with mild psoriasis, unlocking a sizeable new market for the drug, which has been approved since 2014 for moderate to severe cases. “The location of plaques may make the area sensitive to topical treatments or challenging to apply them.”

Labelling 58

Labelling FDA 58

pharmaphorum

SEPTEMBER 11, 2022

Bristol-Myers Squibb’s deucravacitinib– one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe plaque psoriasis. billion oral psoriasis therapy Otezla (apremilast). Otezla was acquired by Amgen for $13.4

Labelling 52

Labelling FDA Immunization 52

Pharmaceutical Technology

JANUARY 10, 2023

It is also eligible for $268m in discovery, regulatory, preclinical, clinical, and commercial milestones and royalties on future sales of Boehringer Ingelheim products. Furthermore, Boehringer Ingelheim will receive royalties on product sales in the future by 3T Biosciences. Free Whitepaper.

Immunization 52

Immunization Compounding Communication 52